European Commission Names Drugs That Won't Need EU 'Safety Feature'
This article was originally published in SRA
Executive Summary
The European Commission has set out the fine detail of the "unique identifier" that in future will have to be affixed to the packaging of practically all prescription medicines marketed in Europe, as required by the EU's directive on falsified medicines1.
You may also be interested in...
EU Updates Guidance On Safety Features For Drugs Under Falsified Medicines Directive
The EU has issued updated guidance on the Falsified Medicines Directive, which gives drug manufacturers until February 2019 to affix 2D barcodes on their products to allow the identification and authentication of individual packs.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.